Fig. 1. Recommendations for clinical trials of probiotics in patients with irritable bowel syndrome (IBS). GI, gastrointestinal; MOA, mechanisms of action; IBS-C, IBS with predominant constipation; IBS-D, IBS with predominant diarrhea; IBS-M, IBS with predominant irregular bowel habit (mixed D/C); PI-IBS, post-infection IBS; QOL, quality of life.
© J Neurogastroenterol Motil
